Serum sickness following a first rituximab infusion with no recurrence after the second one

Clinical and Experimental Rheumatology

Volumn 26, Issue 5, 2008, Pages 967-

  Mehsen, Nadia ^a   Yvon, C M ^a   Richez, C ^a   Schaeverbeke, T ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DEXCHLORPHENIRAMINE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ABNORMAL LABORATORY RESULT; ADULT; ANTIBODY TITER; ARTHRALGIA; CASE REPORT; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INFUSION; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITAL READMISSION; HUMAN; LETTER; MYALGIA; PERICARDITIS; POLYARTHRITIS; PREMEDICATION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RECURRENT DISEASE; SCLERODACTYLY; SCLERODERMA; SERUM SICKNESS; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MIXED CONNECTIVE TISSUE DISEASE; SERUM SICKNESS; YOUNG ADULT;

EID: 57249116208     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (17)

1. COHEN S, EMERY P, GREENWALD M et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of multicenter, randomized, double blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty four weeks. Arthritis Rheum 2006; 54: 2793-806.
2. EDWARDS J, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-Cells-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
3. HERISHANU Y: Rituximab-Induced Serum Sickness. American Journal of Hematology 2002; 70: 329-34.
4. HELLERSTEDT B, AHMED A: Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncology 2003; 14: 1792.
5. CATUOGNO M, REZAI S, PRIORI R, MAGRINI L, VALESINI G: Serum Sickness associated with rituximab in patient with hepatitis C virus-related mixed cryoglobulinemia. Rheumatology 2005; 44: 406.
6. SCHUTGENS REG: Rituximab induced serum sickness. Br J Haematol 2006; 135: 147.
7. TODD D, HELFGOTT S: Serum sickness following treatment with rituximab. J Rheumatol 2007; 34: 430-3.
8. CLARK B, KOTTI G, SHAH A, CONGER N: Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy 2006; 26: 705-8.
9. BENNETT CM, ROGERS ZR, KINNAMON DD et al.: Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 2639-42.
10. WANG J, WILEY JM, LUDDY R, GREENBERG J, FEUERSTEIN MA, BUSSEL JB: Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment. J Pediatr 2005; 146: 217-21.
11. PIJPE J, IMHOFF GWV, SPIJKERVET FKL et al.: Rituximab treatment in patients with primary Sjögren's syndrome. Arthritis Rheum 2005; 52: 2740-50.
12. DEVAUCHELLE-PENSEC V, PENNEC Y, MORVAN J et al.: Improvement of Sjögren's syndrome after two infusions (anti CD 20). Arthritis Rheum 2007; 57: 310-7.
13. GOTTENBERG J-E, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
14. D'ARCY CA, MANNIK M: Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44: 1717-8.
15. DISPERATI P, HICKS L, BUCKSTEIN R: Rituximab-induced serum sickness in a patient with follicular lymphoma. Leuk Lymphoma 2007; 48: 1633-5.
16. FINGER E, SCHEINBERG M: Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13: 94-5.
17. YOAINOU P, JAMIC C, SARAUXA: B cell: a logical target for treatment of rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 318-28.